Disease Areas
News and analysis on disease research and diagnostics.
While ALRN-6924 is first being tested in breast and lung cancer, the firm believes it can help patients with any type of p53-mutated cancer avoid chemo toxicities.
Qlucore Expands Into Bladder Cancer Diagnostics With Lund University Partnership
The company expects that this work to develop and validate classifier models for bladder cancer will lead to a CE mark for its Qlucore Diagnostics software platform.
Day One Biopharmaceuticals Begins Combination Portion of Trial in MAPK-Altered Tumors
Following on a monotherapy study initiated last year, the new study will combine two of Day One's investigational compounds: a Raf kinase inhibitor and a MEK inhibitor.
Seagen Going After Tukysa, Herceptin Combo Approval in HER2-Positive Colorectal Cancer
The company plans to seek accelerated approval for the regimen after seeing a 38 percent objective response rate in the MOUNTAINEER trial.
The lead investigators have also spun out a company, Isabl, aiming to make the approach available to the broader community.